In cancer cells, rapid proliferation leads to abnormal TK1 activation, reducing reliance on TK2, whereas PS cells exhibit selective TK2 downregulation as part of their metabolic transition toward glycolysis and reduced mitochondrial activity. Here, TK2 is linked to cancer.